Xinhua All -Media+｜ my country ’s multiple technology routes develop Omikon vaccine research and development

Feng Zijian, Executive Vice President and Secretary -General of the Chinese Association of Prevention Medicine, said that the real world research on the effectiveness of domestic vaccine prevention in Hong Kong and the Mainland showed that my country's vaccine still has a good protective effect on the severe and death caused by the mutant strains of Omikon. Essence

Feng Zijian introduced that at present, many technical routes in my country have carried out the research and development of unit prices and multi -price Omikon variants. The fast -moving unit price of Omikon variants has been approved by clinical trials and is conducting clinical trials in Zhejiang, Hunan, Hong Kong and other places. The rapid progress of tetramid restructuring protein vaccine has been approved by Phase III clinical trials in the UAE, and related research has been launched. In addition, the research on the new -spectrum vaccine has also been deployed, and the rapid progress of vaccine has been approved by clinical trials and launched related research.

In general, the research and development of Omikon mutant vaccines in China is steadily promoting and rapidly. As long as there is a need, in accordance with relevant regulations, emergency use procedures can be started to provide vaccination. As for whether it is necessary to vaccinate and when to take vaccination specifically for Omikon -containing variants, this problem is not only in my country, but also internationally studying, mainly to study virus mutation and immune escape. (Reporter Gu Tiancheng, Dong Ruifeng)

- END -